During Monday’s current trade, Avago Technologies Ltd (NASDAQ:AVGO)’s shares incline 0.82% to $141.62.
Avago Technologies Ltd (AVGO) declared that its Board of Directors has approved a quarterly, interim cash dividend of $0.40 per ordinary share.
The dividend is payable on June 30, 2015 to shareholders of record at the close of business (5:00 p.m.) Eastern Time on June 19, 2015.
Avago Technologies Limited designs, develops, and supplies semiconductor devices with a focus on analog III-V based products. The company operates through four segments: Wireless Communications, Wired Infrastructure, Enterprise Storage, and Industrial & Other segments. Its product portfolio comprises RF power amplifiers, RF filters, RF front end modules, ambient light sensors, proximity sensors, low noise amplifiers, multimarket-wave mixers, diodes, fiber optic transceivers, serializer/deserializer ASICs, and optical laser and receiver components.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s shares gain 0.96% to $170.67, during the current trading session Monday’s, hitting its highest level.
Traders are betting that Alexion Pharmaceuticals, Inc. (ALXN) will rally by the end of next week.
About 2,000 June 165 calls were purchased for $1.42 to $1.94 yesterday, according to optionMONSTER’s Heat Seeker tracking program. This represents fresh buying, as open interest in the strike was only 195 contracts before the session began.
These long calls lock in the price where investors can buy the stock through expiration in seven sessions, letting them position for a rally at limited cost. They carry less risk than owning shares because the most that can be lost is the price of the options no matter how far the stock might fall. (See our Education section)
The drug maker gapped down in early May on news that it would buy Synageva BioPharma. Shares rebounded but then lost those gains and have been trading sideways in an extremely tight range for the last week.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica.
In a afternoon trade, Quantum Corp (NYSE:QTM)‘s shares plunge -5.88% to $1.76.
Quantum Corp (QTM) has signed a definitive agreement (the “Agreement”) to acquire Columbus Hospital LTACH, LLC (the “LTACH”) http://columbusltach.org/, a company operating a long term acute care hospital in New Jersey (the “Acquisition”).
The LTACH is presently running on a four month unaudited annualized basis of about US$40,000,000 in revenue and about US$13,500,000 of EBITDA. QIIC’s legal counsel engaged independent consultants, Navigant Consulting Inc., to conduct a compliance review which has been accomplished. In addition, an independent external auditor was retained to conduct a financial review of the LTACH, which is ongoing.
Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific. Its scale-out storage and archive products comprise StorNext File System software, which provides file sharing, storage, and archive for content workflows, digital libraries, and data repositories; StorNext Storage Manager software that automatically copies and migrates data between different tiers of storage based on user-defined policies; StorNext appliances that offer predictable file sharing and in purpose-built configurations of metadata controllers, expansion appliances, and disk and archive enabled libraries; and Lattus Object Storage solutions, which enable high volumes of data to be accessible at any time to extract valuable information.
Cadence Design Systems Inc (NASDAQ:CDNS), during its Monday’s current trading session -1.11% loss and closed at $19.66.
Cadence Design Systems Inc (CDNS) declared that Cadence® Innovus™ Implementation System has achieved v1.0 Design Rule Manual (DRM) certification from TSMC for its 16-nanometer FinFET Plus (16FF+) process. The Innovus Implementation System successfully passed rigorous testing and has been validated by TSMC on high-performance reference designs in order to provide customers with a fast path to design closure. Additionally, Cadence and TSMC are collaborating on the certification of the Innovus Implementation System on the 10-nanometer (nm) FinFET process. The certification for the latest version of 10nm DRM and SPICE models is presently on target for completion in June 2015.
The Innovus Implementation System is a next-generation physical implementation tool that enables system-on-chip (SoC) developers to deliver high-quality designs with highly competitive power, performance and area (PPA), while accelerating time to market. The tool provides key technology for the 16FF+ process and supports floor planning, placement and routing with integrated color-/pin-access-/variability-aware timing closure, clock tree and power optimization.
Cadence Design Systems, Inc. develops, sells, leases, and licenses electronic design automation (EDA) software, emulation and prototyping hardware, verification intellectual property (VIP), and design intellectual property (design IP) for semiconductor and electronics systems industries worldwide. It offers functional verification products, counting logic verification software that enables customers to coordinate verification activities across multiple teams and various specialists for verification planning and closure; and system design and verification products for hardware-software verification, in addition to for system power exploration, analysis, and optimization.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
